FBXO32 and cancer: The administration of neutralizing antibodies against these chaperones completely abrogates muscle mass decrease, grip strength reduction and upregulation of atrophic markers, such as Atrogin‐1, UBR2 and LC3‐II, in different mouse models of cancer cachexia, without any effects on the tumour growth.